5 ms·
That's not really always the case. In the case of orphan drugs it would often be much cheaper overall to have the government fund production instead of grantin
by cma 9y ago
That's not really always the case. In the case of orphan drugs it would often be much cheaper overall to have the government fund production instead of granting new exclusive rights to out of patent medications to entities like Skhreli.
Aside from that, more than half of pharma budgets are spent on spent on marketing and patent-workaround redevelopment than on actual productive drug research (even after accounting for new discoveries that sometimes come out of workaround research).
> If we don’t want it to work this way, we need government to spend much more on research,
NIH already funds something close to half of drug research. Even more if you include basic research that has a longer time horizon.
Overall spending would go down, with the side-effect that there would be less penis pill popup ads and way less funding for the Super Bowl halftime show.
- darawk 9y ago> That's not really always the case. In the case of orphan drugs it would often be much cheaper overall to have the government fund production instead of granting new exclusive rights to out of patent medications to entities like Skhreli. You're conflating two things. Orphan drugs are drugs that aren't profitable to produce, for whatever reason. Shkreli did something a bit different and more complex: https://en.wikipedia.org/wiki/Pyrimethamine#Availability_and_price https://en.wikipedia.org/wiki/Pyrimethamine#Availability_and... > NIH already funds something close to half of drug research. Even more if you include basic research that has a longer time horizon. The NIH spends 32[1] billion per year, whereas the global spending is ~160[2] billion. So around 20%. That's a lot, but not nearly half. > Overall spending would go down, with the side-effect that there would be less penis pill popup ads and way less funding for the Super Bowl halftime show. That's a fairly simplistic interpretation of the world. In general, companies tend to be much more efficient at spending their money than governments. We should expect a substantially higher level of productivity per dollar from businesses than we get from government spending. There's definitely a reasonable debate to be had about public funding models, but it ought to be properly contextualized by the realities. [1] - https://www.nih.gov/grants-funding https://www.nih.gov/grants-funding [2] - https://www.statista.com/statistics/309466/global-r-and-d-expenditure-for-pharmaceuticals/ https://www.statista.com/statistics/309466/global-r-and-d-ex... The global R&D spend is
- ergothus 9y ago> In general, companies tend to be much more efficient at spending their money than governments. True, though one has to remember three things: more efficient is not necessarily very efficient; a companies goal is profit, not the best product/result; and companies factor in the ability to fail. The successful company was more effective with their money, but there may be numerous failed efforts and if you factored in their costs the balance is different. After the fact we ascribe great intelligence to the choices of the successful companies rather than the same intelligence but more luck than the unsuccessful companies. Which doesn't contradict any of your points - I'm just pointing out to others tgat it isn't as simple as industry good with money, govt bad with money.
- rectang 9y ago> We should expect a substantially higher level of productivity per dollar from businesses than we get from government spending. Private industry has been very effective indeed at hooking millions of people on opiates. Meanwhile, where are all those new antibiotics? Market competition is an important element missing from government research, but commercial entities have their own pathologies. > There's definitely a reasonable debate to be had about public funding models, but it ought to be properly contextualized by the realities. I favor acknowledging that all markets are constructed, even supposedly "unregulated" ones. The trick is then to construct hybrid models incorporating marketplaces and informed by the limitations of both government and industry.
- pitaj 9y agoI love how you managed you blame the opiate crisis on pharma companies, when it's directly tired to the consequences of drug prohibition by governments.
- nicoburns 9y agoIs the opiate crisis really tied to drug prohibition? I'm sympathetic to the idea of reducig restrictions on dru use, but drugs are prohibited all over the world, and yet it is the US where opiate painkillers are overproscribed that has a big opiates afdiction problem...
- siscia 9y ago> Aside from that, more than half of pharma budgets are spent on spent on marketing and patent-workaround redevelopment than on actual productive drug research (even after accounting for new discoveries that sometimes come out of workaround research). Do you have sources for this? It could really change my point of view on the issue but I need something more...
- mft_ 9y agoI suspect the previous poster is referring to data like this: https://www.washingtonpost.com/news/wonk/wp/2015/02/11/big-pharmaceutical-companies-are-spending-far-more-on-marketing-than-research/?utm_term=.17bb532a646a https://www.washingtonpost.com/news/wonk/wp/2015/02/11/big-p... ...which shows that big pharma generally (Roche excepted) spends more on marketing than R&D. Of course, it's not actually half of all spend, as suggested, as this ignores other operating costs. For example, to take Roche in 2017, sales and royalties brought in ~55.5m CHF. On the flip side, 14.4m CHF was spent on 'cost of sales' (= production costs, overheads, royalties, etc.), 9.5m CHF was spent on 'marketing and distribution', 10.3m CHF was spent on R&D, and 2.5m CHF on 'general and administration'. So in the best case from the WP, R&D > Marketing & distribution, but R&D spend was roughly 28% of total spend. https://www.roche.com/dam/jcr:b70415c0-954f-4a2a-a0e2-47f94bd280e0/en/fb17e.pdf#page=2 https://www.roche.com/dam/jcr:b70415c0-954f-4a2a-a0e2-47f94b...
- rayiner 9y agoMost tech companies also spend more on sales, advertising, and other overhead (SG&A) than on R&D. If you look at the ratios, Microsoft or Google aren’t that far off from say Pfizer.